SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 2
|
records per page:
next >
| last >>
|
| pages: 1 2
|
presentations:
1 to
50 of
99
|
CROI PROGRAM COMMITTEE CHAIR WELCOME TO MONDAY
James A. Hoxie
University of Pennsylvania, Philadelphia, PA, United States
INTRODUCTION OF JOHN NKENGASONG
Wafaa M. El-Sadr
Columbia University, New York, NY, United States
20 YEARS OF PEPFAR: LOOKING BACK, STRIDING FORWARD (ABSTRACT
15)
John Nkengasong
US Department of State, Washington, DC, United States
INTRODUCTION OF ANNA LOK
David L. Thomas
The Johns Hopkins University, Baltimore, MD, United States
THE PATH TO HEPATITIS B CURE (ABSTRACT
16)
Anna S. Lok
University of Michigan, Ann Arbor, MI, United States
INTRODUCTIONS (Part 1)
Adaora Adimora
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
Renee Heffron
University of Alabama at Birmingham, Birmingham, AL, United States
MUCOSAL PHARMACOLOGY OF DOXYCYCLINE FOR BACTERIAL STI PREVENTION IN MEN AND WOMEN (ABSTRACT
118)
Richard Haaland
Centers for Disease Control and Prevention, Atlanta, GA, United States
ANRS 174 DOXYVAC: AN OPEN-LABEL RANDOMIZED TRIAL TO PREVENT STIs IN MSM ON PrEP (ABSTRACT
119)
Jean-Michel Molina
University of Paris Cité, Paris, France
DOXYPEP & ANTIMICROBIAL RESISTANCE IN N. GONORRHOEAE, COMMENSAL NEISSERIA & S. AUREUS (ABSTRACT
120)
Anne F. Luetkemeyer
University of California San Francisco, San Francisco, CA, United States
DOXYCYCLINE POSTEXPOSURE PROPHYLAXIS FOR PREVENTION OF STIs AMONG CISGENDER WOMEN (ABSTRACT
121)
Jenell Stewart
University of Minnesota, Minneapolis, MN, United States
QUESTIONS AND ANSWERS (Part 1)
Renee Heffron
University of Alabama at Birmingham, Birmingham, AL, United States
Adaora Adimora
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
INTRODUCTIONS (Part 2)
Adaora Adimora
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
Renee Heffron
University of Alabama at Birmingham, Birmingham, AL, United States
POTENTIAL IMPACT AND EFFICIENCY OF DOXY-PEP AMONG PEOPLE WITH OR AT RISK OF HIV (ABSTRACT
122)
Michael W. Traeger
Harvard Medical School, Boston, MA, United States
CLUSTER RANDOMISED TRIAL OF RISK-DIFFERENTIATED CARE FOR FEMALE SEX WORKERS: AMETHIST (ABSTRACT
123)
Frances M. Cowan
Liverpool School of Tropical Medicine, Harare, Zimbabwe
RANDOMIZED TRIAL OF COMMUNITY HEALTH WORKER DELIVERED DYNAMIC CHOICE HIV PREVENTION (ABSTRACT
124)
Elijah Kakande
Infectious Diseases Research Collaboration, Kampala, Uganda
CLUSTER RANDOMIZED TRIAL OF INTEGRATED HIV AND SEXUAL & REPRODUCTIVE HEALTH SERVICES (ABSTRACT
125)
Rashida Ferrand
London School of Hygiene & Tropical Medicine, London, United Kingdom
QUESTIONS AND ANSWERS (Part 2)
Renee Heffron
University of Alabama at Birmingham, Birmingham, AL, United States
Adaora Adimora
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
RECENT HIV INFECTION SURVEILLANCE IN BREASTFEEDING WOMEN IN MALAWI: JUL 2019-JUL 2022 (ABSTRACT
126)
Davie D. Chalira
International Training and Education Center for Health, Lilongwe, Malawi
DELIVER: A SAFETY STUDY OF A DAPIVIRINE VAGINAL RING AND ORAL PrEP DURING PREGNANCY (ABSTRACT
127)
Katherine E. Bunge
University of Pittsburgh, Pittsburgh, PA, United States
RANDOMIZED TRIAL OF DYNAMIC CHOICE HIV PREVENTION IN ANTE/POSTNATAL CARE CLINICS (ABSTRACT
128)
Moses Kamya
Makerere University, Kampala, Uganda
MATERNAL POINT-OF-CARE VIRAL LOAD AT DELIVERY IMPACTS INFANT ARV PROPHYLAXIS REGIMEN (ABSTRACT
129)
Anange F. Lwilla
National Institute for Medical Research, Mbeya, Tanzania
QUESTIONS AND ANSWERS (Part 1)
Jennifer Jao
Northwestern University, Chicago, IL, United States
John Kinuthia
Kenyatta National Hospital, Nairobi, Kenya
INTRODUCTIONS (Part 2)
Jennifer Jao
Northwestern University, Chicago, IL, United States
John Kinuthia
Kenyatta National Hospital, Nairobi, Kenya
MULTICOMPONENT INTERVENTION IMPROVES VIRAL SUPPRESSION FOR PREGNANT/POSTPARTUM WOMEN (ABSTRACT
130)
Jane Kabami
Infectious Diseases Research Collaboration, Kampala, Uganda
IMPROVED STRATEGY TO PREVENT HIV POSTNATAL TRANSMISSION: A RANDOMIZED TRIAL (ABSTRACT
131)
Nicholas Nagot
Montpellier University Hospital Centre, Montpellier, France
BIRTH POINT-OF-CARE TEST & TREAT REDUCES EARLY MORTALITY AMONG HIV INFECTED INFANTS (ABSTRACT
132)
Arne Kroidl
Klinikum der Universität München, Munich, Germany
POSTMORTEM CHARACTERIZATION OF HIV-ASSOCIATED UNDER-5 DEATHS IN FOUR CHAMPS SITES (ABSTRACT
133)
Inacio Mandomando
Centro de Investigação em Saúde de Manhica, Maputo, Mozambique
SARS-CoV-2 IN CHILDREN & ADOLESCENTS LIVING WITH HIV IN EUROPE & SOUTH AFRICA (ABSTRACT
134)
Charlotte Jackson
University College London, London, United Kingdom
QUESTIONS AND ANSWERS (Part 2)
Jennifer Jao
Northwestern University, Chicago, IL, United States
John Kinuthia
Kenyatta National Hospital, Nairobi, Kenya
SimpliciTB RESULTS AND HEPATIC SAFETY OF PRETOMANID REGIMENS +/- PYRAZINAMIDE (ABSTRACT
109)
Muge Cevik
University of St Andrews, St Andrews, United Kingdom
STANDARD VS DOUBLE DOSE DOLUTEGRAVIR IN HIV-ASSOCIATED TUBERCULOSIS: WEEK 48 RESULTS (ABSTRACT
110)
Rulan Griesel
University of Cape Town, Cape Town, South Africa
INCREASED TB PREVENTIVE THERAPY COVERAGE WITH INTEGRATED COMMUNITY-BASED IPT AND ART (ABSTRACT
111)
Adrienne E. Shapiro
University of Washington, Seattle, WA, United States
RCT OF ECONOMIC INCENTIVES FOR REDUCED ALCOHOL USE AND INH ADHERENCE AMONG PWH (ABSTRACT
112)
Gabriel Chamie
University of California San Francisco, San Francisco, CA, United States
QUESTIONS AND ANSWERS (Part 1)
Constance A. Benson
University of California San Diego, San Diego, CA, United States
David Wyles
Denver Health Medical Center, Denver, CO, United States
EFFICACY AND SAFETY OF 8-WK TUBERCULOSIS TREATMENT REGIMENS IN THE TRUNCATE-TB TRIAL (ABSTRACT
113)
Nicholas Paton
National University of Singapore, Singapore, Singapore
PanACEA SUDOCU COMBINATION DOSE-FINDING TRIAL SHOWS SUTEZOLID IS A SAFE OXAZOLIDINONE (ABSTRACT
114)
Norbert Heinrich
LMU University Hospital, Munich, Germany
cccDNA SILENCING AND LIMITED DECAY OF INFECTED CELLS IN HIV-HBV (HBeAG-) DURING NUCs (ABSTRACT
115)
Maraake Taddese
The Johns Hopkins University, Baltimore, MD, United States
PREDICTORS OF HEPATITIS B TREATMENT RESPONSE IN PEOPLE WITH HIV/HBV COINFECTION (ABSTRACT
116)
Anchalee Avihingsanon
Thai Red Cross AIDS Research Center, Bangkok, Thailand
PAGE-B SCORE TO ESTIMATE THE HEPATOCELLULAR CARCINOMA RISK IN PEOPLE WITH HIV AND HBV (ABSTRACT
117)
Bernard Surial
University Hospital of Bern, Bern, Switzerland
QUESTIONS AND ANSWERS (Part 2)
Constance A. Benson
University of California San Diego, San Diego, CA, United States
David Wyles
Denver Health Medical Center, Denver, CO, United States
INTRODUCTIONS (Part 1)
Molly Ohainle
University of California Berkeley, Berkeley, CA, United States
Theodora Hatziioannou
Rockefeller University, New York, NY, United States
LENACAPAVIR INHIBITS VIRION MATURATION BY BLOCKING FORMATION OF CAPSID PENTAMERS (ABSTRACT
100)
Mamuka Kvaratskhelia
University of Colorado, Aurora, CO, United States
INHIBITION OF NEUTRAL SPHINGOMYELINASE 2 BLOCKS HIV-1 MATURATION (ABSTRACT
101)
Abdul Waheed
National Cancer Institute, Frederick, MD, United States
INVESTIGATING THE ROLE OF CAPSID STABILITY IN INNATE IMMUNE SENSING OF HIV-1 CORES (ABSTRACT
102)
Jenna E. Eschbach
Washington University in St. Louis, St. Louis, MO, United States
MUTATIONS OUTSIDE INTEGRASE LEAD TO HIGH-LEVEL RESISTANCE TO DOLUTEGRAVIR (ABSTRACT
103)
Yuta Hikichi
National Cancer Institute, Frederick, MD, United States
QUESTIONS AND ANSWERS (Part 1)
Theodora Hatziioannou
Rockefeller University, New York, NY, United States
Molly Ohainle
University of California Berkeley, Berkeley, CA, United States
MX2 ANTIVIRAL SPECIFICITY IS AFFECTED BY GTPase ACTIVITY AND CAPSID-CypA INTERACTIONS (ABSTRACT
104)
Melissa Kane
University of Pittsburgh, Pittsburgh, PA, United States
HOST CELL GLYCOSYLATION DIFFERENTIALLY AFFECTS CCR5- AND CXCR4-TROPIC HIV-1 INFECTION (ABSTRACT
105)
Hannah L. Itell
Fred Hutchinson Cancer Research Center, Seattle, WA, United States
THE FRACTION OF CELLS WITH UNSPLICED HIV RNA IS NOT ASSOCIATED WITH PLASMA VIREMIA (ABSTRACT
106)
Adam A. Capoferri
National Cancer Institute, Frederick, MD, United States
HUMAN ANTI-ACE2 MONOCLONAL ANTIBODIES AS PAN-SARBECOVIRUS PROPHYLACTIC AGENTS (ABSTRACT
107)
Paul D. Bieniasz
Rockefeller University, New York, NY, United States
|
<< first | < prev
page:
of 2
|
records per page:
next >
| last >>
|
| pages: 1 2
|
presentations:
1 to
50 of
99
|
